Johnson & Johnson Invests $1B in Pennsylvania Cell Therapy Facility, Ranks 9th in Gartner Supply Chain

Johnson & Johnson has announced plans to invest over $1 billion in the development of a new biomanufacturing facility in Pennsylvania. The planned site will focus on cell therapy production, aiming to enhance its capabilities in advanced biomanufacturing technologies. Johnson & Johnson has also secured ninth place in Gartner's 2026 Rankings of the Global Supply Chain Top 25, demonstrating how operational excellence in logistics translates directly into reliable access to medicine for patients.

According to Gartner, Johnson & Johnson's supply chain demonstrated resilience through this period of disruption, placing the company among the top 10 global performers at a time when maintaining consistent medicine supply has become increasingly difficult. Gartner notes that Johnson & Johnson built "a strong, resilient supply base by integrating its suppliers as an expansion of their network and capabilities". The approach uses what the research firm describes as "end-to-end resource orchestration".

Johnson & Johnson's Transcend programme focuses on transforming end-to-end business processes, aiming to strengthen technical reliability across the supply chain while maintaining consistent quality for medicines reaching healthcare facilities. The programme modernises foundational transactional processes, harmonising them into a single ERP platform, a standardised system for growth and efficiency gains. The company states this work will address end-of-life system exposure that could affect operations later this decade.

Johnson & Johnson deployed an AI-powered digital assistant within its MedTech manufacturing business. According to the company, the technology reduced the need for human intervention by 70%.

Johnson & Johnson committed to building a contact lens manufacturing plant in Jacksonville, US. The US$1bn investment includes new advanced manufacturing and packaging technologies and a distribution facility. The company states the facility will "scale the Company's U.S. Vision operations, enhance supply chain resilience, and meet the needs of more than 40 million patients".

Johnson & Johnson entered a voluntary arrangement with the Trump administration earlier in 2026. The pharmaceutical company agreed to reduce medication costs in return for expanded domestic operations.